Avicanna Past Earnings Performance
Past criteria checks 0/6
Avicanna has been growing earnings at an average annual rate of 16.5%, while the Pharmaceuticals industry saw earnings growing at 4.9% annually. Revenues have been growing at an average rate of 68.1% per year.
Key information
16.5%
Earnings growth rate
40.7%
EPS growth rate
| Pharmaceuticals Industry Growth | 7.3% |
| Revenue growth rate | 68.1% |
| Return on equity | -93.5% |
| Net Margin | -29.9% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Avicanna makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 25 | -7 | 16 | 0 |
| 31 Mar 24 | 22 | -7 | 15 | 0 |
| 31 Dec 23 | 17 | -9 | 14 | 0 |
| 30 Sep 23 | 12 | -12 | 13 | 0 |
| 30 Jun 23 | 6 | -14 | 12 | 0 |
| 31 Mar 23 | 4 | -16 | 11 | 0 |
| 31 Dec 22 | 4 | -15 | 11 | 0 |
| 30 Sep 22 | 4 | -16 | 12 | 0 |
| 30 Jun 22 | 4 | -16 | 13 | 0 |
| 31 Mar 22 | 4 | -15 | 12 | 0 |
| 31 Dec 21 | 3 | -17 | 13 | 0 |
| 30 Sep 21 | 2 | -24 | 14 | 0 |
| 30 Jun 21 | 2 | -29 | 15 | 0 |
| 31 Mar 21 | 2 | -34 | 17 | 0 |
| 31 Dec 20 | 2 | -33 | 17 | 0 |
| 30 Sep 20 | 2 | -25 | 19 | 0 |
| 30 Jun 20 | 1 | -24 | 21 | 0 |
| 31 Mar 20 | 0 | -21 | 22 | 0 |
| 31 Dec 19 | 0 | -22 | 22 | 0 |
| 30 Sep 19 | 0 | -18 | 18 | 0 |
| 30 Jun 19 | 0 | -14 | 14 | 0 |
| 31 Mar 19 | 0 | -11 | 11 | 0 |
| 31 Dec 18 | 0 | -7 | 8 | 0 |
| 30 Sep 18 | 0 | -5 | 6 | 0 |
| 31 Dec 17 | 0 | -3 | 3 | 0 |
Quality Earnings: 0NN is currently unprofitable.
Growing Profit Margin: 0NN is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 0NN is unprofitable, but has reduced losses over the past 5 years at a rate of 16.5% per year.
Accelerating Growth: Unable to compare 0NN's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 0NN is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (1.5%).
Return on Equity
High ROE: 0NN has a negative Return on Equity (-93.46%), as it is currently unprofitable.